Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.
Ther Apher Dial
; 28(4): 557-571, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38499495
ABSTRACT
INTRODUCTION:
Several calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the impact of calcimimetics on the management of serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis.METHODS:
A systematic literature search through October 2023 and a meta-analysis were conducted on the effects of upacicalcet, etelcalcetide, evocalcet, and cinacalcet on serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis; we searched PubMed, Ovid MEDLINE, and the Cochrane Central Register of Controlled Trials, and 21 studies comprising 6371 patients undergoing dialysis were included.RESULTS:
Participants treated with calcimimetics had lower serum calcium and phosphate levels than placebo.CONCLUSION:
Calcimimetics significantly reduced serum calcium and phosphate levels compared to placebo in patients with secondary hyperparathyroidism undergoing dialysis, independent of therapeutic strategy or concomitant vitamin D treatment.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fosfatos
/
Ensaios Clínicos Controlados Aleatórios como Assunto
/
Cálcio
/
Diálise Renal
/
Calcimiméticos
/
Hiperparatireoidismo Secundário
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article